Has this billion-dollar fund made the right call on ARRY, VRX, and HIMX?
Analyst expected NDA acceptance- but believes the FDA news importantly lowers regulatory risk for ARRY.
Forecasting a potential $500 million yearly sales opportunity ahead, the analyst lifts price target on Array.
Three key biopharma trades from the highly-successful $78 billion Renaissance fund
Array Biopharma Inc (NASDAQ:ARRY) shares are dipping almost 8% after the discouraging news broke that the biotech firm has decided to withdraw its …
In a research report published Friday, Cantor analyst Mara Goldstein reiterated an Overweight rating on shares of Array Biopharma Inc (NASDAQ:ARRY) with a …
Array Biopharma Inc (NASDAQ:ARRY) shares were soaring 17% yesterday on back of a second fiscal quarter update that has given investors signs of …
Array Biopharma Inc (NASDAQ:ARRY) investors celebrated Monday’s positive COLUMBUS Phase 3 results for its BRAF-mutant melanoma cancer treating pipeline drug BRAFI encorafenib, an oral small …
Array Biopharma Inc Leerink’s top analyst Michael Schmidt was out today with a favorable report on shares of Array Biopharma Inc (NASDAQ:ARRY), raising the …
It is a day full of great news for the biotech-verse as Array Biopharma Inc (NASDAQ:ARRY) shares are shooting 54% today on back …
